Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike
Jenna J. Guthmiller, Olivia Stovicek, Jiaolong Wang, et al.
mBio (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Jianmin Zuo, Alexander C. Dowell, Hayden Pearce, et al.
Nature Immunology (2021) Vol. 22, Iss. 5, pp. 620-626
Open Access | Times Cited: 387
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Fatima Amanat, Mahima Thapa, Tinting Lei, et al.
Cell (2021) Vol. 184, Iss. 15, pp. 3936-3948.e10
Open Access | Times Cited: 275
Delayed production of neutralizing antibodies correlates with fatal COVID-19
Carolina Lucas, Jon Klein, Maria E. Sundaram, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1178-1186
Open Access | Times Cited: 243
Antibody tests for identification of current and past infection with SARS-CoV-2
Tilly Fox, Julia Geppert, Jacqueline Dinnes, et al.
Cochrane library (2022) Vol. 2022, Iss. 11
Open Access | Times Cited: 176
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
Carl Graham, Jeffrey Seow, Isabella Huettner, et al.
Immunity (2021) Vol. 54, Iss. 6, pp. 1276-1289.e6
Open Access | Times Cited: 143
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
Natalia Ortega, Marta Ribes, Marta Vidal, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 132
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets
Haley L. Dugan, Christopher T. Stamper, Lei Li, et al.
Immunity (2021) Vol. 54, Iss. 6, pp. 1290-1303.e7
Open Access | Times Cited: 120
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, et al.
Seminars in Immunology (2021) Vol. 55, pp. 101533-101533
Open Access | Times Cited: 105
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Levente Zsichla, Viktor Müller
Viruses (2023) Vol. 15, Iss. 1, pp. 175-175
Open Access | Times Cited: 66
SARS-CoV-2 immunity in animal models
Chen Zhao, Yaochang Yuan, Qing‐Tao Hu, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 2, pp. 119-133
Open Access | Times Cited: 14
Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons
Lyle R. Petersen, Samira Sami, Nga Vuong, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 9, pp. e3066-e3073
Open Access | Times Cited: 110
Functional importance of the D614G mutation in the SARS-CoV-2 spike protein
Cody B. Jackson, Lizhou Zhang, Michael Farzan, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 538, pp. 108-115
Open Access | Times Cited: 99
The success of SARS-CoV-2 vaccines and challenges ahead
Kanta Subbarao
Cell Host & Microbe (2021) Vol. 29, Iss. 7, pp. 1111-1123
Open Access | Times Cited: 87
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
Chun-Yang Lin, Joshua Wolf, David C. Brice, et al.
Cell Host & Microbe (2021) Vol. 30, Iss. 1, pp. 83-96.e4
Open Access | Times Cited: 86
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
Jérémy Dufloo, Ludivine Grzelak, Isabelle Staropoli, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 5, pp. 100275-100275
Open Access | Times Cited: 81
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
Cole J. Batty, Mark T. Heise, Eric M. Bachelder, et al.
Advanced Drug Delivery Reviews (2020) Vol. 169, pp. 168-189
Open Access | Times Cited: 76
Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
Diego Ojeda, María Mora Gonzalez Lopez Ledesma, Horacio M. Pallarés, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 1, pp. e1009161-e1009161
Open Access | Times Cited: 71
The role of B cells in COVID-19 infection and vaccination
Shiru Chen, Fei Guan, Fabio Candotti, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
SARS-CoV-2 epitope–specific CD4 + memory T cell responses across COVID-19 disease severity and antibody durability
Ryan Nelson, Yuezhou Chen, Olivia Venezia, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 45
Protective neutralizing epitopes in SARS‐CoV‐2
Hejun Liu, Ian A. Wilson
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 76-92
Open Access | Times Cited: 39
Immune responses in mildly versus critically ill COVID-19 patients
Hamid Nasrollahi, Atefe Ghamar Talepoor, Zahra Saleh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 38
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
Tuksin Jearanaiwitayakul, Mathurin Seesen, Runglawan Chawengkirttikul, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 768-768
Open Access | Times Cited: 49
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 40
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
John Tyler Sandberg, Renata Varnaitė, Wanda Christ, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 7
Open Access | Times Cited: 40
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Elizabeth M. Anderson, Shuk Hang Li, Moses Awofolaju, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111496-111496
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top